Y Intercept Hong Kong Ltd acquired a new stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) during the first quarter, according to its most recent disclosure with the SEC. The fund acquired 55,138 shares of the company’s stock, valued at approximately $855,000.
Other hedge funds also recently made changes to their positions in the company. General Atlantic L.P. purchased a new stake in Nurix Therapeutics in the 4th quarter worth approximately $92,899,000. Morgan Stanley lifted its holdings in Nurix Therapeutics by 115.9% during the fourth quarter. Morgan Stanley now owns 4,881,069 shares of the company’s stock valued at $92,594,000 after purchasing an additional 2,620,323 shares in the last quarter. Rubric Capital Management LP bought a new position in shares of Nurix Therapeutics in the fourth quarter worth approximately $46,930,000. Braidwell LP bought a new position in shares of Nurix Therapeutics in the fourth quarter worth approximately $41,428,000. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of Nurix Therapeutics by 195.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,248,361 shares of the company’s stock worth $61,622,000 after purchasing an additional 2,149,268 shares in the last quarter.
Nurix Therapeutics Price Performance
Shares of NRIX opened at $23.06 on Monday. The firm has a market cap of $2.39 billion, a P/E ratio of -6.68 and a beta of 1.80. Nurix Therapeutics, Inc. has a 1 year low of $8.19 and a 1 year high of $25.08. The company has a 50 day simple moving average of $18.44 and a two-hundred day simple moving average of $17.36.
Insider Buying and Selling at Nurix Therapeutics
In other Nurix Therapeutics news, insider Gwenn Hansen sold 5,394 shares of the stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $20.00, for a total transaction of $107,880.00. Following the completion of the transaction, the insider owned 115,005 shares of the company’s stock, valued at $2,300,100. This represents a 4.48% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Houte Hans Van sold 14,055 shares of the firm’s stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $16.60, for a total value of $233,313.00. Following the transaction, the chief financial officer owned 37,592 shares of the company’s stock, valued at approximately $624,027.20. The trade was a 27.21% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 25,051 shares of company stock worth $434,466. Corporate insiders own 6.70% of the company’s stock.
Key Nurix Therapeutics News
Here are the key news stories impacting Nurix Therapeutics this week:
- Positive Sentiment: Roche collaboration news was a major catalyst: Nurix said it entered a global partnership for bexobrutideg with potential total payments of up to $2.3 billion, including a $700 million upfront payment. Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- Positive Sentiment: Royal Bank of Canada raised its price target on Nurix Therapeutics from $30 to $33 and reiterated an outperform rating, signaling confidence in upside from current levels.
- Positive Sentiment: Stifel Nicolaus lifted its target from $34 to $40 and maintained a buy rating, while Needham and BTIG also reaffirmed buy ratings with targets of $34 and $32, respectively, adding to the bullish analyst tone.
- Neutral Sentiment: Nurix reported second-quarter 2026 results with an EPS loss of $0.81 and revenue of $9.04 million, both below estimates, which kept focus on the company’s pipeline and partnership potential rather than near-term fundamentals. Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- Negative Sentiment: The earnings miss may cap enthusiasm somewhat, as the company posted a wider loss than expected and revenue came in well below consensus. Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates
Wall Street Analysts Forecast Growth
NRIX has been the topic of several recent analyst reports. BTIG Research restated a “buy” rating and set a $32.00 price objective on shares of Nurix Therapeutics in a research report on Friday. Needham & Company LLC reaffirmed a “buy” rating and issued a $34.00 target price on shares of Nurix Therapeutics in a report on Friday. Truist Financial increased their price target on Nurix Therapeutics from $32.00 to $34.00 and gave the stock a “buy” rating in a research note on Friday. HC Wainwright raised their price target on Nurix Therapeutics from $32.00 to $34.00 and gave the company a “buy” rating in a report on Friday. Finally, Wall Street Zen upgraded Nurix Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday. Twelve equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $33.77.
View Our Latest Stock Report on Nurix Therapeutics
Nurix Therapeutics Company Profile
Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.
The company’s pipeline includes multiple programs in various stages of development.
Featured Stories
- Five stocks we like better than Nurix Therapeutics
- 3 Rare-Earth ETFs That Help Investors Balance Exposure and Risk
- Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs
- Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing
- This Dividend ETF Choice Could Shape Your Income Strategy Through 2026
Want to see what other hedge funds are holding NRIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report).
Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
